A Phase II Trial of Revlimid (Lenalidomide) and Low Dose Vidaza (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes

Trial Profile

A Phase II Trial of Revlimid (Lenalidomide) and Low Dose Vidaza (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2013

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top